AstraZeneca Acquires Teneotwo For Over $1.27 Billion
ADC评论
July 6, 2022
On July 5, AstraZeneca announced that it intends to acquire biotech company TeneoTwo and will receive a bispecific molecular therapy in Phase 1 clinical trials.
